Navigation Links
Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis
Date:3/31/2011

NEW YORK, March 31, 2011 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., today announced positive results from a 59 patient, placebo controlled, double-blind  Phase II clinical trial of obeticholic acid (OCA) given as monotherapy to patients with primary biliary cirrhosis (PBC).  The study evaluated the effects of 10 mg and 50 mg of OCA compared with placebo in patients with elevated alkaline phosphatase (AP).  AP is a liver enzyme routinely used to evaluate the clinical status and disease progression of PBC patients.

At the end of the 12 week treatment period, both doses of OCA produced statistically highly significant reductions in AP, the primary endpoint, compared with the patients receiving placebo (changes: 10mg:  -45%; 50mg:  -38%; placebo:  0%; p < 0.0001 both doses versus placebo). There were also significant improvements in other liver enzymes, including gamma-glutamyl transferase. In addition, serum markers of inflammation and immunity also improved with significant reductions of C-reactive protein (CRP), and immunoglobulin M (IgM), which is closely associated with the autoimmune dysfunction in PBC.  Pruritus (itch) was seen more commonly in the OCA treated patients and increased with dose; otherwise, all other adverse events were generally similar across the groups.

PBC is a chronic autoimmune disease of the liver marked by the slow progressive destruction of the small bile ducts within the liver which may lead to liver failure and the need for liver transplantation. PBC primarily afflicts women with up to 300,000 patients estimated in developed countries.  There is only one drug approved to treat the disease, ursodeoxycholic acid (UDCA), and up to 50% of PBC patients on UDCA therapy continue to be at significant risk of progression to cirrhosis.

Kris V. Kowdley, MD, Director of the Center for Liver Disease at Virginia Mason Medical Center, in Seattle, Washington and a princ
'/>"/>

SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease
2. Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals Obeticholic Acid (INT-747) in NASH
3. Intercept Pharmaceuticals to Collaborate With NIDDK on Study of Obeticholic Acid (INT-747) in Nonalcoholic Steatohepatitis (NASH)
4. Intercept Pharmaceuticals Raises $25 Million Series B Financing
5. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
6. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
7. Reportlinker Adds Top 500 Pharmaceuticals Industry Report (Global)
8. Reportlinker Adds Top 200 Biopharmaceuticals Industry Report (Global)
9. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
10. Vanda Pharmaceuticals to Evaluate Tasimelteon in Major Depression
11. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015 The Physician-Patient Alliance for ... July 28, 2015, "Surviving Your Hospital Stay: Physician-Patient ... Patient Safety." A sentence was omitted ... "PPAHS is a member of the National ... more information on the National Coalition to Promote ...
(Date:7/31/2015)... 2015 Egalet Corporation (Nasdaq: EGLT ... focused on developing, manufacturing and marketing innovative pain ... announced underwritten public offering of 7,666,667 shares of ... of $11.25 per share. The shares of common ... upon the exercise in full by the underwriters ...
(Date:7/31/2015)... July 31, 2015 Magnaquest, ... video, data and cloud computing operators has signed ... pharma giant for Internet of Things (IoT) related ... offered on subscription model.      (Logo: ... is striving for business innovations to make healthcare ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2
... Ltd announces that new market research reports on Healthcare Equipment & ... , , ... of Lifestyle Disorders Driving Growth. The report provides key data ... covered include Diabetes care Devices, Orthopedic Devices and Cardiovascular Devices. The study ...
... , June 16 The first in a planned ... treatments for millions of Indian cancer patients has been officially opened ... Oncology and Fortis Healthcare, is equipped with advanced radiotherapy equipment and ... , , ...
Cached Medicine Technology:Healthcare Equipment & Services Research June Updates by MarketPublishers.com 2Healthcare Equipment & Services Research June Updates by MarketPublishers.com 3Healthcare Equipment & Services Research June Updates by MarketPublishers.com 4Varian Medical Systems Equips International Oncology's First Comprehensive Cancer Center in India 2Varian Medical Systems Equips International Oncology's First Comprehensive Cancer Center in India 3
(Date:8/1/2015)... ... 2015 , ... The condition where veins are enlarged and gnarled is known ... and discomfort. Those who spend a lot of time on their feet and standing ... doing what it can to create awareness and provide a cure in observance of ...
(Date:8/1/2015)... , ... August 01, 2015 , ... Brig and Lita ... are announcing the unification of their Healthy Home mission with the HOPE Movement of ... years, the founders of both companies have agreed to join their missions of purpose ...
(Date:8/1/2015)... ... ... Lume Wellness creators Alex, Robert, and Sam have announced update 3.0.1 to ... , The app is designed to track various metrics of wellness, including physical activity, ... health and use this information for positive behavior modification. Lume Wellness keeps track of ...
(Date:8/1/2015)... ... ... March 19, 2015 Phil Valentine – the Executive Director of Connecticut Community for Addiction Recovery ... off Springer Mountain and heading north. Since that day, Phil has hiked over 1400 miles ... by friends and family. He visited CCAR and left an inspirational message to his ...
(Date:7/31/2015)... ... 31, 2015 , ... When the weather turned hot and warm-season turfgrasses, such ... sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for short. Incidentally, both ... this new type of sod, Super-Sod is giving away red Adirondack chairs with the ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2
... from stress urinary incontinence (SUI), a condition where sneezing, ... ,“We try to treat patients with conservative ... exercises, and addressing problems such as chronic coughing, infections ... says Andrew Sambell, M.D., a urologist on the medical ...
... well known; a bite on the body that allows the ... what happens next that causes the virus //to multiply and ... Hughes Medical Institute (HHMI) international scholar in Argentina have been ... dengue virus multiply, which is the main cause of the ...
... new research study on the higher-than-average mortality rates of the ... staying indoors in their apartments// as being responsible for the ... mortality rates in areas where the businesses were run-down and ... less comfortable going to and hence preferred staying indoors making ...
... California-Davis and Justus-Liebig University in Giessen, Germany said that ... disease by understanding how certain mice focused their attention ... , ‘Without a measure of cognitive deficit in ... research into new diagnostic methods, treatments and cures is ...
... (PTSD) isn't limited to soldiers or witnesses of a horrifying ... stroke, or heart surgery. Not only does PTSD cause emotional// ... the progression of heart disease, reports the August issue of ... heart-related PTSD is that the trauma comes from within. Sufferers ...
... of bone healing can be primarily dome by ... as the primary imaging// technique, according to a ... of Vienna in Vienna, Austria. ,Forty-three ... or spinal fusions who'd undergone MDCT and conventional ...
Cached Medicine News:Health News:The Dengue Virus Unplugged 2Health News:The Dengue Virus Unplugged 3Health News:Staying Indoors Responsible for 1995 Heat Wave Killings 2Health News:Staying Indoors Responsible for 1995 Heat Wave Killings 3Health News:Scientist Study New Treatment Modality for Psychiatric Disorders Using Mice 2Health News:Scientist Study New Treatment Modality for Psychiatric Disorders Using Mice 3
15mm Open Blades, 28mm Maximum Spread; Available in small(S) and large (L), in stainless steel....
9mm Gently Curved Jaws, without lock; in Titanium....
8mm angled shaft with tip at 90 degree angle wtih rounded tear drop point; Tip available in left, right and center; (Right-SQT-225 and Left -SQT-227) In Titanium....
2.0mm Rounded Tip, 12mm From Tip to Bend Gently Curved, 15mm Shaft; In Titanium...
Medicine Products: